Arcutis Biotherapeutics (ARQT) Price & Analysis

Compare

879 Followers

ARQT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$8.03 - $18.15

Previous CloseN/A

Volume446.87K

Average Volume (3M)1.78M

Market Cap

$2.03B

Enterprise Value$1.70B

Total Cash (Recent Filing)$191.13M

Total Debt (Recent Filing)$110.16M

Price to Earnings (P/E)―

Beta1.18

Next Earnings

Nov 05, 2025

EPS Estimate

-0.09

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.13

Shares Outstanding119,905,075

10 Day Avg. Volume1,832,479

30 Day Avg. Volume1,784,694

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.84

Enterprise Value/Revenue6.45

Enterprise Value/Gross Profit7.24

Enterprise Value/Ebitda-24.80

Forecast

1Y Price Target

$22.16

Price Target Upside30.58% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

Bulls Say, Bears Say

Bulls Say

Insurance CoverageThe entire Zoryve portfolio is covered by the three national PBMs, and management reported that over 80% of prescriptions are covered by insurance.

Label ExpansionZoryve sales growth should see meaningful growth driven by the Kowa collaboration and recent/new label expansions.

Prescription GrowthTotal product sales beat consensus, with management reporting 19% prescription growth, and GTN remains stable in the 50% range.

Bears Say

Medicare ReimbursementMedicare reimbursement has stalled due to IRA-related changes, though Medicare accounts for less than 25% of the company’s TAM.

Product DevelopmentThe company disclosed that it is discontinuing development of ARQ-255 following Phase 1b results in alopecia areata did not meet the company's threshold for advancing development.

Arcutis Biotherapeutics News

Arcutis Biotherapeutics announces new Zoryve data at EADV congress

Arcutis Biotherapeutics (ARQT) announced that new data on Zoryve efficacy across three common skin conditions-seborrheic dermatitis, atopic dermatitis,...

2d ago

ARQT

Arcutis Biotherapeutics sybmits sNDA for ZORYVE Cream 0.3%

Arcutis Biotherapeutics (ARQT) announced the submission of a supplemental New Drug Application to the U.S. Food and Drug...

15d ago

ARQT

Arcutis Biotherapeutics’ Earnings Call: Growth Amid Challenges

Arcutis Biotherapeutics Inc (($ARQT)) has held its Q2 earnings call. Read on for the main highlights of the...

1M ago

ARQT

Arcutis Biotherapeutics price target raised to $25 from $20 at TD Cowen

TD Cowen raised the firm’s price target on Arcutis Biotherapeutics (ARQT) to $25 from $20 and keeps a...

1M ago

ARQT

Arcutis Biotherapeutics: Promising Growth Driven by Zoryve’s Success and Strategic Initiatives

Analyst Douglas Tsao of H.C. Wainwright reiterated a Buy rating on Arcutis Biotherapeutics, boosting the price target to...

1M ago

ARQT

Arcutis Biotherapeutics price target raised to $22 from $19 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Arcutis Biotherapeutics (ARQT) to $22 from $19 and keeps a...

1M ago

ARQT

Arcutis Biotherapeutics Reports Strong Q2 2025 Growth

Arcutis Biotherapeutics Inc ( ($ARQT) ) has released its Q2 earnings. Here is a breakdown of the information...

1M ago

ARQT

Arcutis Biotherapeutics: Strong Performance and Growth Potential Drive Buy Rating

Analyst Tyler Van Buren from TD Cowen maintained a Buy rating on Arcutis Biotherapeutics and increased the price...

1M ago

ARQT

Arcutis Biotherapeutics reports Q2 EPS (13c), consensus (16c)

Reports Q2 revenue $81.5M, consensus $73.67M. “We continue to advance our strategy to become the leading medical dermatology...

1M ago

ARQT

Carvana upgraded, Ulta Beauty downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

2M ago

Arcutis Biotherapeutics initiated with a Neutral at Goldman Sachs

Goldman Sachs initiated coverage of Arcutis Biotherapeutics (ARQT) with a Neutral rating and $18 price target The company’s...

2M ago

ARQT

Arcutis Biotherapeutics Completes Promising Psoriasis Treatment Study

Arcutis Biotherapeutics Inc (($ARQT)) announced an update on their ongoing clinical study. Arcutis Biotherapeutics Inc. recently completed a...

2M ago

ARQT

Arcutis Biotherapeutics assumed with an Overweight at Morgan Stanley

Morgan Stanley assumed coverage of Arcutis Biotherapeutics (ARQT) with an Overweight rating and a price target of $20,...

3M ago

ARQT

Arcutis announces ZORYVE cream receives strong recommendation from AAD

Arcutis Biotherapeutics (ARQT) announced that ZORYVE cream 0.15% has received a strong recommendation in the focused guideline update...

3M ago

ARQT

ARQT FAQ

What was Arcutis Biotherapeutics’s price range in the past 12 months?

Arcutis Biotherapeutics lowest stock price was $8.03 and its highest was $18.15 in the past 12 months.

What is Arcutis Biotherapeutics’s market cap?

Arcutis Biotherapeutics’s market cap is $2.03B.

When is Arcutis Biotherapeutics’s upcoming earnings report date?

Arcutis Biotherapeutics’s upcoming earnings report date is Nov 05, 2025 which is in 48 days.

How were Arcutis Biotherapeutics’s earnings last quarter?

Arcutis Biotherapeutics released its earnings results on Aug 06, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.145 by $0.015.

Is Arcutis Biotherapeutics overvalued?

According to Wall Street analysts Arcutis Biotherapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Arcutis Biotherapeutics pay dividends?

Arcutis Biotherapeutics does not currently pay dividends.

What is Arcutis Biotherapeutics’s EPS estimate?

Arcutis Biotherapeutics’s EPS estimate is -0.09.

How many shares outstanding does Arcutis Biotherapeutics have?

Arcutis Biotherapeutics has 119,905,075 shares outstanding.

What happened to Arcutis Biotherapeutics’s price movement after its last earnings report?

Arcutis Biotherapeutics reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.145. Following the earnings report the stock price went down -8.073%.

Which hedge fund is a major shareholder of Arcutis Biotherapeutics?

Currently, no hedge funds are holding shares in ARQT

Arcutis Biotherapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-57.33%

Trailing 12-Months

Asset Growth

-20.76%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Arcutis Biotherapeutics (ARQT) Earnings & Revenues

Historic Earnings Reports

ARQT Company Deck

ARQT Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call for Arcutis Biotherapeutics highlighted strong revenue and prescription growth driven by the ZORYVE franchise and recent FDA approval. Despite seasonal factors expected to moderate growth and challenges in Medicare Part D coverage, the positive cash flow and strategic plans suggest a promising outlook.View all ARQT earnings summaries

ARQT Stock 12 Month Forecast

Average Price Target

$22.16

▲(30.58% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","30":"$30","12.75":"$12.75","18.5":"$18.5","24.25":"$24.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$29.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22.16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$22.16</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.29</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,12.75,18.5,24.25,30],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.32,16.372307692307693,17.424615384615386,18.47692307692308,19.52923076923077,20.581538461538464,21.633846153846154,22.686153846153847,23.73846153846154,24.790769230769232,25.843076923076925,26.895384615384614,27.947692307692307,{"y":29,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.32,15.846153846153847,16.372307692307693,16.89846153846154,17.424615384615386,17.950769230769232,18.47692307692308,19.003076923076925,19.52923076923077,20.055384615384618,20.581538461538464,21.107692307692307,21.633846153846154,{"y":22.16,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.32,15.240769230769232,15.161538461538461,15.082307692307692,15.003076923076923,14.923846153846153,14.844615384615384,14.765384615384615,14.686153846153847,14.606923076923076,14.527692307692307,14.448461538461538,14.369230769230768,{"y":14.29,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.88,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.55,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.67,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.42,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.93,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.24,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.69,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.98,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.65,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.48,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.75,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.29,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.32,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >